tirzepatide compound illegal March 10, 2025: Patients transitioning from compounded diabetes / weight loss injections: Stick to licensed sources – Partnership for Safe Medicines Compounded Tirzepatide: Legal & Safe

Description

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

Tirzepatide belongs to a class of medications called GLP-1 receptor agonists, which work by helping the body produce more insulin and reducing sugar production in the liver

The most effective approach combines establishing strong dietary habits before stopping, increasing physical activity (especially resistance training), working with a provider on a transition plan, tracking food intake during the adjustment period, and scheduling regular weight monitoring appointments